Net Income Margin Trends in Leading Pharmaceutical Companies

A Comparative Analysis Over the Last 8 Quarters

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis delves into the net income margins of four major players: GlaxoSmithKline (GSK), AstraZeneca (AZN), Takeda (TAK), and Eli Lilly (LLY) over the past two years.

Key Insights

• Eli Lilly has shown remarkable performance with an average net income margin of approximately 21%, peaking at 26% in Q1 2024. This indicates strong profitability and efficient cost management.
• GlaxoSmithKline maintains a steady average net income margin of around 16%, reflecting consistent financial health.
• AstraZeneca follows closely with an average net income margin of 15%, showcasing stable growth.
• Takeda lags behind with an average net income margin of just 6%, highlighting potential areas for improvement.

Missing Data

It's important to note that some data points for 2025 are missing, which could affect the overall trend analysis. However, the available data provides a clear picture of the financial trajectories of these companies.

Conclusion

This comparative analysis offers valuable insights into the financial performance of these pharmaceutical giants, helping investors and stakeholders make informed decisions. Stay tuned for more updates as new data becomes available.